Pre-made Cofetuzumab Pelidotin benchmark antibody (Whole mAb ADC, anti-PTK7 therapeutic antibody, Anti-CCK-4/CCK4 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Cofetuzumab Pelidotin benchmark antibody (Whole mAb ADC, anti-PTK7 therapeutic antibody, Anti-CCK-4/CCK4 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cofetuzumab pelidotin (INN;[1] development code PF-66472) is an experimental antibody-drug conjugate in development for the treatment of cancer. It was created by Stemcentrx and is being developed by Pfizer.[2] The drug is an anti-PTK7 monoclonal antibody linked to auristatin-11, an auristatin microtubule inhibitor.[3][4]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-785-1mg	1mg	Inquiry
GMP-Bios-INN-785-10mg	10mg	Inquiry
GMP-Bios-INN-785-100mg	100mg	Inquiry
GMP-Bios-INN-785-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Cofetuzumab Pelidotin Biosimilar, Whole Mab Adc, Anti-Ptk7 Antibody: Anti-CCK-4/CCK4 therapeutic antibody Drug Conjugate
INN Name	Cofetuzumab Pelidotin
Target	PTK7
Format	Whole mAb ADC
Derivation	Humanized
Species Reactivity	human
CH1 Isotype	IgG1 - kappa
VD LC	IgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Pfizer (New York NY USA) / AbbVie Inc. (North Chicago IL USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0